Osteogenesis Imperfecta – Pipeline Review, H2 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Osteogenesis
Imperfecta – Pipeline Review, H2 2018”
drug pipelines has been
added to ResearchAndMarkets.com’s offering.

Osteogenesis Imperfecta – Pipeline Review, H2 2018,
provides comprehensive information on the therapeutics under development
for Osteogenesis Imperfecta (Genetic Disorders), complete with analysis
by stage of development, drug target, mechanism of action (MoA), route
of administration (RoA) and molecule type. The guide covers the
descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.

The Osteogenesis Imperfecta (Genetic Disorders) pipeline guide also
reviews of key players involved in therapeutic development for
Osteogenesis Imperfecta and features dormant and discontinued projects.
The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1,
1, 1, 2 and 1 respectively.

Osteogenesis Imperfecta (Genetic Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Companies Featured

  • Amgen Inc.
  • Bone Therapeutics SA
  • Genzyme Corp.
  • Mereo Biopharma Group plc
  • Mesentech Inc.
  • SOM Biotech SL

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/z3s7cf/osteogenesis?w=4


Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Musculoskeletal
Disorders Drugs